# Proteome-based Immunotherapy of Brain Metastases From Breast Cancer

> **NCT01782274** · PHASE2,PHASE3 · UNKNOWN · sponsor: **NeuroVita Clinic** · enrollment: 60 (estimated)

## Conditions studied

- Neoplasm Metastasis

## Interventions

- **BIOLOGICAL:** Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes
- **BIOLOGICAL:** Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes

## Key facts

- **NCT ID:** NCT01782274
- **Lead sponsor:** NeuroVita Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2018-12
- **Final completion:** 2020-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-10-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01782274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01782274, "Proteome-based Immunotherapy of Brain Metastases From Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01782274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*